MENU
Investigator-Initiated Trials (IIT), also known as Investigator-Initiated Studies (IIS), are unsolicited research studies in which the investigator (usually an individual or institution, collaborative study groups) takes the lead in designing, planning, and conducting the study, as opposed to a pharmaceutical company or sponsor. These studies play a crucial role in advancing scientific knowledge regarding Celltrion products, exploring new uses for existing treatments, and addressing clinical questions to expand patient care.
The investigator assumes a central role and are primarily responsible for the design, execution, and oversight of the study. Their responsibilities encompass scientific,legal, regulatory and ethical aspects of the trial.
Investigators bear the legal and regulatory responsibilities of the trial sponsor for the conduct and management of the study, complying with applicable laws and regulations. Such obligations associated with the conduct of the study include, but are but not limited to, the following:
Celltrion US is currently accepting IIT proposals in the following areas of Interest
Areas of Interest Drug: Zymfentra (Infliximab-dyyb) Subcutaneous (SC) Injection |
Real World Studies (Prospective, Retrospective, Observational)
|
IV Vs. SC IFX dosing |
Attributes of ideal candidates for IFX SC Therapy |
Therapeutic Drug Monitoring |
Switching from IV to SC IFX
|
Dose Escalation due to loss of response |
SC IFX dosing in high (body mass index (BMI) Patients |
SC IFX in Patients with Perianal Disease/Fistulizing Crohn’s Disease |
Crohn’s Disease (CD) and Ulcerative Colitis (UC) disease modification |
Cost Efficiency of SC IFX utilization |
Optimal monitoring of disease, including non-invasive mucosal healing monitoring tools (e.g., ultrasound) |
Assessment of biomarkers aimed at identifying various factors influencing response |
Precision Therapy Strategy |
Explore Dosing Strategies to enhance disease management |
Treatment decisions in rural/underserved populations |
The IIT support provided by Celltrion USA is for US researchers only. Celltrion USA will provide support as either a research grant and/or supply of an investigational medicinal product (IMP) provided that align with the company-defined areas of strategic interest.
Celltrion USA accepts concept proposal submission and full studyproposalsubmissions for IITs. Investigators requesting IIT support should submit their initial concept proposalsubmission to grants_usa@celltrionhc.com
If you need assistance prior to submission and during the review process, please contact your Celltrion USA Field Based Medical Science Liaison for more information.If you do not know who your local Celltrion USA Medical representative is, pleasesend an email to medical_usa@celltrionhc.com and you will be connected with your Medical Science Liaison.
A brief concept proposal must provide sufficient information for Celltrion USA to evaluate its potential and decide whether to request full study proposal. When submitting a concept proposal please include the following (if applicable):
Upon request, a full study proposal submission must contain enough detail about the research study to enable the Celltrion USA to make an evaluation on support. When submitting a full study proposal, the following information will be requested (if applicable):
Please Note: For all research grant proposals that include monetary support the investigator should submit a completed copy of the payee IRS W-9 Form.
The Celltrion USA IIT review process involves the following steps:
Step 1: Concept Proposal submission
Step 2: Internal Review by CTUS of concept proposal.
Step 3: Full Proposal submission requestby HCP
Full Proposal Submission: If a concept proposal shows potential, a request for full study proposalsubmission will follow.
Step 4: Internal Committee review by Celltrion USA
Cookie technology helps us to provide you with the best possible experience when you visit this website. If you continue without changing your settings, you agree to the cookies on this website. For more information about our Cookie policy, please see the link to our Privacy Policy at the bottom of the page